Wir verwenden standardmäßig essenzielle Cookies (Anmeldung, deine gespeicherten Ziele/Stacks). Mit deiner Erlaubnis aktivieren wir außerdem datenschutzfreundliche Analytik (Vercel Web Analytics, anonyme Ladezeit-Metriken) und Fehler-Replay-Diagnostik (Sentry — DOM-Snapshots nur, wenn ein Fehler auftritt), damit wir Bugs schneller beheben können. Mehr über Cookies erfahren
Sam7.0
SAMe – Forschung
Gemischte Evidenz
20 begutachtete Studien
Was die Evidenz sagt
Gemischte Evidenz
Die Studien sind gespalten: SAMe half in 1 von 3 Fällen, der Rest war ergebnislos oder zeigte keinen Nutzen.
Die meiste Evidenz stammt aus hochwertigen Meta-Analysen und randomisierten Studien, veröffentlicht 2004–2026 mit einer typischen Studiengröße von 656 Teilnehmenden.
Basierend auf 20 Studien · 4 Meta-Analysen · 5 RCTs · 6,474 Teilnehmende insgesamt
Konfidenz
Hohe Konfidenz
Was die Studien gefunden haben
1geholfen2unklar· 17 weitere ohne bewertete Effektdaten
Joint pain & arthritisIn klinischen Studien vergleichbar mit NSAR bei Arthroseschmerzen · 4-8 weeks
Zu wenige bewertete Studien2 Studien
Liver health
Zu wenige bewertete Studien1 Studie
Heart & blood pressure
Zu wenige bewertete Studien1 Studie
Energy & fatigue
Zu wenige bewertete Studien1 Studie
Safety profile
Zu wenige bewertete Studien1 Studie
In Zahlen
Aus 14 Studien mit messbaren Effekten gezogen
Untersuchte Personen
6,474
typische Studie: 656 Personen
Stärkste Designs
9
4 gepoolt, 5 randomisiert
Zeigte Nutzen
33%
1/3 Studien
Wie lange Studien liefen
1–3 Monate
2
Untersuchte Populationen
Patients with depression2
Adults with mild depression1
Participants receiving SAM supplementation1
Patients with liver diseases1
Aktives Forschungsgebiet
16 Studien in den letzten 5 Jahren · Neueste Meta-Analyse: 2025
200420152026
1Depression response ratesMeta-Analysen=1,049 · large study2025
This review demonstrates that certain supplements, such as eicosapentaenoic acids and Rhodiola rosea, are therapeutic options for mild depression.
Urata M et al. · Neuropsychopharmacology reports (2025)
Kein klarer Effekt
← SchlechterKein EffektBesser →
A meta-analysis found no significant difference in response rates between the two treatments (risk ratio [RR] = 0.96, 95% CI: 0.78-1.18) or dropout rates (RR = 1.08, 95% CI: 0.62-1.88).
Eicosapentaenoic acid and Rhodiola rosea demonstrated significant improvements in depressive symptoms compared to placebo.
Conversely, S-adenosylmethionine did not produce significant improvements relative to placebo.
5Pain reductionMeta-AnalyseCited 40×n=656 · large study2009
The current systematic review is inconclusive, hampered by the inclusion of mainly small trials of questionable quality.
Rutjes AW et al. · The Cochrane database of systematic reviews (2009)
Kein klarer Effekt
← SchlechterKein EffektBesser →
For pain, the analysis indicated a small SMD of -0.17 (95% CI -0.34 to 0.01), corresponding to a difference in pain scores between SAMe and placebo of 0.4 cm on a 10 cm VAS, with no between trial heterogeneity (I(2) = 0).
For function, the analysis suggested a SMD of 0.02 (95% CI -0.68 to 0.71) with a moderate degree of between-trial heterogeneity (I2 = 54%).
The current systematic review is inconclusive, hampered by the inclusion of mainly small trials of questionable quality.
The results of SAMe versus placebo as a monotherapy, SAMe versus imipramine or escitalopram as a monotherapy, and SAMe versus placebo as an adjunctive therapy, showed no significant difference in depression with SAMe compared to the comparison treatment.
Conclusions SAMe may provide relief of depression symptoms similar to imipramine or escitalopram.
However, the results of the comparisons should be interpreted with caution due to the small number of studies and the large range of SAMe doses that were used in the included trials.
Appropriate levels of these micronutrients should then be monitored at all stages of development for a healthier brain.
Bekdash RA · International journal of molecular sciences (2023)
Studies in human and animal models have indicated the importance of the optimal levels of methyl donors on brain health and behavior across the lifespan.
Imbalances in the levels of these micronutrients during critical periods of brain development have been linked to epigenetic alterations in the expression of genes that regulate normal brain function.
We present studies that support the link between imbalances in the levels of methyl donors, epigenetic alterations, and stress-related disorders.
In the present study, we have observed that adjunctive SAMe can have positive benefit on male arousal and erectile dysfunction, independent of improvement in depressive symptoms.
Dording CM et al. · European psychiatry : the journal of the Association of European Psychiatrists (2012)
In the present study, we have observed that adjunctive SAMe can have positive benefit on male arousal and erectile dysfunction, independent of improvement in depressive symptoms.
These findings are preliminary, and warrant replication.
CLINICAL TRIALS.GOV IDENTIFIER: NCT00093847; titled 'Optimizing the Effectiveness of Selective Serotonin Reuptake Inhibitors (SSRIs) in Treatment-Resistant Depression', accessible at: http://clinicaltrials.gov/ct2/show/NCT00093847.
We also discuss emerging themes and open questions, emphasizing how advances in structural and spectroscopic techniques continue to deepen our understanding of these complex and vital enzymatic processes.
Böhm M et al. · Annual review of biochemistry (2026)
The interplay among redox-active cofactors, metal ions, and protein scaffolds highlights nature's ingenuity in generating, controlling, and utilizing radicals.
We discuss amino acid-based radicals (tyrosyl, tryptophan, cysteinyl, glycyl, and DOPA), radicals derived from molecular oxygen (in heme, manganese, copper, and nonheme iron enzymes), and cofactor-based radicals (specifically adenosylcobalamin and radical S-adenosylmethionine enzymes).
We devote special attention to ribonucleotide reductases as a prime example of evolutionary convergence of radical mechanisms.
This systematic-review examined the effects of SAMe.
Karimi K et al. · Amino acids (2026)
Starvation suppresses mTORC1 activity, leading to reduced ribosome biogenesis and translation while promoting autophagy to meet cellular energy demands.
We discuss the adaptive mechanisms by which reduced levels of acetyl-CoA, amino acids, EP300, glucose, insulin, and S-adenosylmethionine inhibit mTORC1 and simultaneously induce autophagy.
Additionally, we describe the adaptive role that glucagon, Sestrin2, and urea play to inhibit mTORC1 and how eIF5A, glucagon, spermidine, and TFEB induce autophagy.
Overall, the review highlights the importance of harmonized analytical protocols and matrix-specific validation to enable reliable clinical interpretation of SAM and SAH as methylation biomarkers.
Kuty A, Kocur A, Molasy B, Wrzosek M. · Biomedicines (2026)
The review also discusses preanalytical variables, including biological matrix selection, sample handling, and storage conditions.
LC-MS/MS methods are compared with alternative techniques, such as immunoassays, with respect to sensitivity, specificity, matrix effects, and clinical relevance.
Additionally, the review summarizes the concentration ranges of SAM and SAH, and their ratio, in healthy and patient populations, noting current standardization limitations.
This review summarizes current knowledge on the role of the MAT1A /SAMe axis in ALD pathophysiology, emphasizing molecular functions and critically evaluating preclinical and clinical evidence for potential therapy.
Experimental models demonstrate that SAMe supplementation restores methylation capacity, replenishes GSH, reduces oxidative stress, and improves mitochondrial function and liver histology.
Preservation of mitochondrial MATα1 also protects against ALD, underscoring its importance in hepatocellular health.
Clinical exploration of SAMe in early-stage ALD suggests potential benefit and motivates continued investigation into treatment strategies that build on and extend beyond supplementation.
The review also addresses SAMe's potential use in managing other psychiatric disorders and neurological diseases.
Labhade S, Bhole R, Jain S. · East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan (2024)
This review aims to determine the role of S-adenosylmethionine (SAMe) supplementation as an alternative therapeutic option, particularly for individuals with inadequate responses to conventional antidepressive treatments.
The effects of SAMe on depression are analysed through its role in modulating neurotransmitter metabolism, reducing neuroinflammation, enhancing neuroplasticity, and regulating gene expression.
These mechanisms may contribute to the efficacy of SAMe in treating depression, particularly in treatment-resistant cases.
There is evidence of a potential benefit of SAMe as an intervention to help with symptoms across the range of post-concussive sequelae and syndromes commonly seen in military mTBI.
Schieffler DA et al. · Military medicine (2022)
There is evidence of a potential benefit of SAMe as an intervention to help with symptoms across the range of post-concussive sequelae and syndromes commonly seen in military mTBI.
Since the discovery of SAMe in 1952, this pleiotropic molecule has shown the significance of its involvement in several metabolic cascades in such disparate systems as epigenetics, bioenergetics, DNA methylation, neurotransmitter systems, and potential usefulness in military TBI.
Significant limitations include disparate presentations seen in patients with mild TBI, those with post-concussive syndrome, as well as those with comorbid depression and posttraumatic stress disorder.
17Osteoarthritis symptomsCrossoverCited 59×n=61 · small study2004
SAMe has a slower onset of action but is as effective as celecoxib in the management of symptoms of knee osteoarthritis.
Najm WI et al. · BMC Musculoskeletal Disorders (2004)
On the first month of Phase 1, celecoxib showed significantly more reduction in pain than SAMe (p = 0.024).
By the second month of Phase 1, there was no significant difference between both groups.
On most functional health measures both groups showed a notable improvement from baseline, however no significant difference between SAMe and celecoxib was observed.
18Plasma S-Adenosylhomocysteine levelsRCTn=40 · small study2025
This is the first demonstration of a nutritional product's effectiveness in decreasing plasma levels of SAH in otherwise healthy individuals with elevated SAH and normal Hcy.
Pohl F et al. · Nutrition, metabolism, and cardiovascular diseases : NMCD (2025)
Spürbar Nutzen
← SchlechterKein EffektBesser →
The test product significantly lowered plasma SAH levels by approximately 12% and increased S-Adenosylmethionine (SAM): SAH ratio by approximately 26% after 12 weeks of supplementation compared to baseline.
This is the first demonstration of a nutritional product's effectiveness in decreasing plasma levels of SAH in otherwise healthy individuals with elevated SAH and normal Hcy.
Hence, this test product offers a unique opportunity for investigating the impact of lowering plasma SAH on the risk of developing CVD and other diseases.
20Liver function and mortalityÜbersichtCited 155×2012
SAMe synthesis is depressed in chronic liver disease and so there has been considerable interest in the utility of SAMe to ameliorate disease severity.
Anstee QM, Day CP · Journal of Hepatology (2012)
SAMe participates in multiple cellular reactions as the precursor for the synthesis of glutathione and principal methyl donor.
Pre-clinical data confirm that SAMe depletion can exacerbate liver injury and support a hepatoprotective role for SAMe therapy.
To date no large, high-quality randomised clinical trials have been performed that establish clinical utility in specific disease states.